AOD-9604 — Peptide Dosing Protocols reference

patient_educationexpert_opinion · status: needs_provider_review

Details

Author: —

Citation: —

Summary (generated — provider review required)

AOD-9604 Dosage Guide: Peptide Protocol, Reconstitution & Fat Loss (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols AOD-9604 Dosing Guide: Protocol, Reconstitution & Safety (2026) Protocol / Research Dosing Guide AOD-9604 Dosing Guide: Protocol, Reconstitution & Safety (2026) An evidence-based AOD-9604 research guide covering what this HGH fragment is, what human trials actually showed, dosing and reconstitution math, side effects, FDA status, and how it compares with HGH and GLP-1 drugs. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Ion Peptide AOD-9604 Powder View Ion Peptide Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Blood Tests Clinical Evidence Storage & Handling Troubleshooting Regulatory Status AOD-9604 Comparisons Route Context Related Protocols FAQ References AOD-9604 Quick Start AOD-9604 is a 16-amino-acid synthetic peptide. It corresponds to the last 15 amino acids of human growth hormone (positions 177-191) with an extra tyrosine added at one end to stabilize the molecule.

The original source document remains the source of truth. Generated summaries are not authoritative.

Linked assets (9) · phenotypes (0)

evidence_reference, dosing_reference, safety_reference, mechanism, monitoring_reference

Findings (179) · awaiting review (142)

dosing · pending

1 unit on a U-100 syringe equals 0.01 mL.

regulatory · pending

AOD-9604 is not approved by the FDA for any therapeutic use.

regulatory · pending

CTs; ~20% weight loss at 72 weeks Approved drug entries reflect U.S.

regulatory · pending

Information here is drawn from published research and regulatory documents.

dosing · pending

Insulin Syringes (U-100) Daily subcutaneous injections.

safety · pending

The practical takeaway: AOD-9604 has a clean safety profile in trials but a failed Phase 2b efficacy endpoint.

regulatory · pending

GLP-1 and GIP/GLP-1 drugs have strong Phase 3 efficacy and clear FDA-approved labels for weight management.

regulatory · pending

Each compound has its own evidence and regulatory profile.

dosing · pending

The volume of water you add changes the concentration and therefore how many syringe units equal each dose.

dosing · pending

By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Ion Peptide AOD-9604 Powder View Ion Peptide Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Blood Tests Clinical Evidence Storage & Handling Troubleshooting Regulatory Status AOD-9604 Comparisons Route Context Related Protocols FAQ References AOD-9604 Quick Start AOD-9604 is a 16-amino-acid synthetic peptide.

dosing · pending

Route Subcutaneous injection is the format with the most published research-context use.

dosing · pending

Common research dose 300-500 mcg/day in research planning context, drawn from the dose range used across the published Phase 1/2 trials.

dosing · pending

Measure At 3.0 mL reconstitution of a 5 mg vial, 1 unit on a U-100 syringe is roughly 16.67 mcg.

regulatory · pending

Status Not FDA-approved.

regulatory · pending

Reviewed by FDA against compounding inclusion in December 2024.

dosing · pending

AOD-9604 Dosing Protocol & Schedule Published human research with AOD-9604 used both intravenous and oral routes.

dosing · pending

Subcutaneous injection is the most common research-context format today, but no published human pharmacokinetic study has formally characterized subcutaneous AOD-9604 (this gap was specifically called out in FDA's December 2024 review).

dosing · pending

The dosing context below summarizes publ

dosing · pending

It is not a dosing recommendation.

dosing · pending

Common research-planning structure (subcutaneous) Research-context daily protocol with a 5 mg vial reconstituted to 3.0 mL (~1.667 mg/mL).

dosing · pending

Phase Initial 4 weeks Daily Dose 300 mcg Volume 0.18 mL Units (U-100) 18 units Phase Maintenance (weeks 5-12) Daily Dose 500 mcg Volume 0.30 mL Units (U-100) 30 units Phase Optional extension Daily Dose 300-500 mcg Volume 0.18-0.30 mL Units (U-100) 18-30 units Phase Daily Dose Volume Units (U-100) Initial 4 weeks 300 mcg 0.18 mL 18 units Maintenance (weeks 5-12) 500 mcg 0.30 mL 30 units Optional extension 300-500 mcg 0.18-0.30 mL 18-30 units This summarizes the published research-context dose range (commonly cited 300-500 mcg/day).

dosing · pending

Studies that used 1 mg/day in oral and intravenous trials did not show meaningfully better outcomes than lower doses, and higher doses were associated with more reports of headache, diarrhea, and gastrointestinal effects.

dosing · pending

Approach Short trial arm Duration 12 weeks Review Point Week 12 Notes METAOD005 used 12 weeks at oral doses 1-30 mg/day in 300 obese adults.

dosing · pending

Approach Phase 2b trial arm Duration 24 weeks Review Point Week 12 and 24 Notes METAOD006 (OPTIONS) used 24 weeks at oral doses 0.25, 0.5, or 1 mg/day in 502 obese adults; prima

dosing · pending

Approach Duration Review Point Notes Short trial arm 12 weeks Week 12 METAOD005 used 12 weeks at oral doses 1-30 mg/day in 300 obese adults.

dosing · pending

Phase 2b trial arm 24 weeks Week 12 and 24 METAOD006 (OPTIONS) used 24 weeks at oral doses 0.25, 0.5, or 1 mg/day in 502 obese adults; primary endpoint not met.

safety · pending

Evidence boundary The published trial record describes safety more clearly than efficacy.

dosing · pending

AOD-9604 Supplies Needed Plan based on subcutaneous research dosing of 300-500 mcg/day from a 5 mg vial reconstituted with 3.0 mL bacteriostatic water.

dosing · pending

Peptide Vials 5 mg AOD-9604 vials.

dosing · pending

Each vial provides about 10 days of dosing at 500 mcg/day or about 16-17 days at 300 mcg/day after reconstitution.

dosing · pending

Cycle length Planning note 8 weeks 5 vials Covers a 4-week 300 mcg lead-in plus a 4-week 500 mcg phase.

dosing · pending

12 weeks 8 vials Covers a 4-week 300 mcg lead-in plus 8 weeks at 500 mcg.

dosing · pending

16 weeks 11 vials Covers a 4-week 300 mcg lead-in plus 12 weeks at 500 mcg.

dosing · pending

8 weeks 5 vials Covers a 4-week 300 mcg lead-in plus a 4-week 500 mcg phase.

dosing · pending

0.3 mL / 30-unit U-100 syringes are the most practical for typical 18-30 unit draws.

dosing · pending

Bacteriostatic Water 3.0 mL per 5 mg vial

dosing · pending

10 mL bottles are the common research-supply size.

dosing · pending

Cycle length Planning note 8 weeks 2 x 10 mL bottles 5 vials use 15 mL total; second bottle covers margin and overdraw.

dosing · pending

12 weeks 3 x 10 mL bottles 8 vials use 24 mL total; third bottle covers margin.

Processing

Processed into 30 searchable sections.